Literature DB >> 2721212

Continuous arteriovenous hemofiltration in premature infants.

G Zobel1, E Ring, W Müller.   

Abstract

Five critically ill premature infants with acute renal failure (ARF) and hypervolemia were treated by continuous arteriovenous hemofiltration (CAVH). Prostacyclin was used to prevent hemofilter clotting. Mean treatment duration was 53.6 +/- 14 h. Mean blood flow rates of 1.6 +/- 0.22 ml/min and filtration fractions of 17.2 +/- 3.7% produced mean ultrafiltration rates of 8.3 +/- 3.1 ml/kg.h. Fluid overload was easily corrected by means of CAVH. The mean prehemofiltration serum creatinine and urea levels were 2.3 +/- 0.4 and 77 +/- 29.7 mg/dl; the mean posthemofiltration levels were 2.38 +/- 0.43 and 92 +/- 34.4 mg/dl, respectively. Hemofilter clotting occurred every 14 h. Urinary output was restored in three infants. Three of the five infants died, but none of the deaths was related to ARF or CAVH. CAVH is a safe and simple method to control fluid and metabolic imbalances in critically ill premature infants.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2721212     DOI: 10.1097/00003246-198906000-00010

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  3 in total

1.  Haemodynamic effects of arteriovenous and venovenous haemofiltration in piglets.

Authors:  J H Reeves; W W Butt
Journal:  Pediatr Nephrol       Date:  1996-02       Impact factor: 3.714

2.  Anticoagulation in patients with acute kidney injury undergoing kidney replacement therapy.

Authors:  Rupesh Raina; Ronith Chakraborty; Andrew Davenport; Patrick Brophy; Sidharth Sethi; Mignon McCulloch; Timothy Bunchman; Hui Kim Yap
Journal:  Pediatr Nephrol       Date:  2021-10-19       Impact factor: 3.651

3.  Peritoneal dialysis for acute renal failure in children.

Authors:  V M Reznik; W R Griswold; B M Peterson; A Rodarte; M E Ferris; S A Mendoza
Journal:  Pediatr Nephrol       Date:  1991-11       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.